Blocking immunological checkpoints such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1), and programmed cell death protein-1 (PD-1) (2, 3), has made a great contribution to the immunotherapy of various cancers in recent years. This evidence concerns the gene PDCD1 and cancer.